Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ADH1B | P00325 | 1/20 | 0.38 |
| ▸ | ADH1C | P00326 | 1/20 | 0.38 |
| ▸ | ADH1A | P07327 | 1/20 | 0.38 |
| ▸ | ADH4 | P08319 | 1/20 | 0.38 |
| ▸ | ADH7 | P40394 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.37 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.36 |
| ▸ | FDPS | P14324 | 3/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6180258 | 1.00 | SPHK1 (0.41) | SPHK1LMNAADH1BADH1CADH1A | |
| SCHEMBL2004432 | 0.83 | SPHK1 (0.43) | SPHK1LMNAADH1BADH1CADH1A | |
| SCHEMBL20355948 | 0.77 | SPHK1 (0.42) | SPHK1LMNAADH1BADH1CADH1A | |
| SCHEMBL10386188 | 0.75 | LCK (0.48) | ACE2GPR84FFAR1CA1ZDHHC7 | |
| SCHEMBL2798260 | 0.75 | LCK (0.48) | ACE2GPR84FFAR1CA1ZDHHC7 | |
| SCHEMBL16059072 | 0.75 | LCK (0.48) | ACE2GPR84FFAR1CA1ZDHHC7 | |
| SCHEMBL2798264 | 0.75 | LCK (0.48) | ACE2GPR84FFAR1CA1ZDHHC7 | |
| SCHEMBL2799138 | 0.75 | LCK (0.48) | ACE2GPR84FFAR1CA1ZDHHC7 | |
| SCHEMBL15791893 | 0.75 | LCK (0.48) | ACE2GPR84FFAR1CA1ZDHHC7 | |
| SCHEMBL16059073 | 0.75 | LCK (0.48) | ACE2GPR84FFAR1CA1ZDHHC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1291345-B1 | Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors | WARNER LAMBERT CO (US) | 2005-11-30 | — | — | EP | disclosed |
| US-6924276-B2 | Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2005-08-02 | — | — | US | disclosed |
| US-20040039208-A1 | Process for making n-aryl-anthranilic acids and their derivatives | CHEN MICHAEL HUAI GU (US) | 2004-02-26 | — | — | US | disclosed |
| US-20030099632-A1 | Method for preparing a purified matrix metalloproteinase | MUELLER WILLIAM THOMAS (US) | 2003-05-29 | — | — | US | disclosed |
| EP-1313694-A1 | PROCESS FOR MAKING N-ARYL-ANTHRANILIC ACIDS AND THEIR DERIVATIVES | WARNER-LAMBERT COMPANY (US) | 2003-05-28 | — | — | EP | disclosed |
| US-20030087924-A1 | Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors | SORENSON RODERICK JOSEPH (US) | 2003-05-08 | — | — | US | disclosed |
| WO-2003033018-A1 | METHOD FOR PREPARING PURIFIED MATRIX METALLOPROTEINASE | WARNER-LAMBERT COMPANY LLC (US) | 2003-04-24 | — | — | WO | disclosed |
| EP-1304373-A2 | Method for preparing a purified matrix metalloproteinase | WARNER-LAMBERT COMPANY (US) | 2003-04-23 | — | — | EP | disclosed |
| EP-0739970-B1 | Gas oil compositions and gas oil additives | KAO CORP (JP) | 2003-03-19 | — | — | EP | disclosed |
| EP-1291345-A1 | Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2003-03-12 | — | — | EP | disclosed |
| WO-2002018319-A1 | PROCESS FOR MAKING N-ARYL-ANTHRANILIC ACIDS AND THEIR DERIVATIVES | WARNER-LAMBERT COMPANY LLC (US) | 2002-03-07 | — | — | WO | disclosed |
| US-6190574-B1 | OIL ADDITIVE | KAO CORPORATION (JP) | 2001-02-20 | — | — | US | disclosed |
| US-5855628-A | LOW SULFUR, MIXTURE OF MONOGLYCERIDE AND DIGLYCERIDE | KAO CORPORATION (JP) | 1999-01-05 | — | — | US | disclosed |
| EP-0739970-A1 | Gas oil compositions and gas oil additives | KAO CORPORATION (JP) | 1996-10-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039208-A1 | Process for making n-aryl-anthranilic acids and their derivatives | AADAC, AHR, AADAT | SPHK1 4468/4885LMNA 767/4885ADH1B 199/4885 |
| US-20030099632-A1 | Method for preparing a purified matrix metalloproteinase | MMP3, MMP25, MMP7 | SPHK1 3320/4885LMNA 799/4885ADH1B 1117/4885 |
| US-20030087924-A1 | Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors | MMP13, MMP3, MMP9 | SPHK1 2383/4885LMNA 2506/4885ADH1B 1764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.